CYP2B6 18492T→C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 2268-2273

  Manosuthi, Weerawat ^a   Sukasem, Chonlaphat ^b   Thongyen, Suped ^a   Nilkamhang, Samruay ^a   Manosuthi, Sukanya ^a   Sungkanuparph, Somnuek ^b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; DNA; EFAVIRENZ; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; LAMIVUDINE; RIFAMPICIN; TENOFOVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CYTOCHROME P 450 CYP2B6; CYTOCHROME P-450 CYP2B6; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; GENE MUTATION; HAPLOTYPE; HETEROZYGOTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TUBERCULOSIS; WILD TYPE; YOUNG ADULT; BLOOD; GENETICS;

ADULT; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; COINFECTION; FEMALE; HAPLOTYPES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE INHIBITORS; TUBERCULOSIS;

EID: 84896947818     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02384-13     Document Type: Article

References (27)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2013. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, Washington, DC. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 1 April 2013.
2. Desta Z, Saussele T, Ward B, Blievernicht J, Li L, Klein K, Flockhart DA, Zanger UM. 2007. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8:547-558. http://dx.doi.org/10.2217/14622416.8.6. 547. (Pubitemid 46947859)
3. Mutlib AE, Chen H, Nemeth GA, Markwalder JA, Seitz SP, Gan LS, Christ DD. 1999. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab. Dispos. 27:1319-1333.
4. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. 2003. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306:287-300. http://dx.doi.org/10.1124/jpet.103.049601. (Pubitemid 36734384)
5. Breen RA, Swaden L, Ballinger J, Lipman MC. 2006. Tuberculosis and HIV co-infection: a practical therapeutic approach. Drugs 66:2299-2308. http://dx.doi.org/10.2165/00003495-200666180-00003. (Pubitemid 46072443)
6. Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, Prommool V, Ruxrungtham K, Team NRS. 2009. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R study. Clin. Infect. Dis. 48:1752-1759. http://dx.doi.org/10.1086/599114.
7. Bonnet M, Bhatt N, Baudin E, Silva C, Michon C, Taburet AM, Ciaffi L, Sobry A, Bastos R, Nunes E, Rouzioux C, Jani I, Calmy A, CARINEMO study group. 2013. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infect. Dis. 13:303-312. http://dx.doi.org/10.1016/S1473-3099(13)70007-0.
8. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, Ruxrungtham K, Vibhagool A, Rattanasiri S, Thakkinstian A. 2006. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 20:131-132. http://dx.doi.org/10.1097/01.aids.0000196181. 18916.9b. (Pubitemid 41818129)
9. Manosuthi W, Sungkanuparph S, Thakkinstian A, Vibhagool A, Kiertiburanakul S, Rattanasiri S, Prasithsirikul W, Sankote J, Mahanontharit A, Ruxrungtham K. 2005. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS 19:1481-1486. http://dx.doi.org/10.1097/01.aids.0000183630. 27665.30. (Pubitemid 41400693)
10. WHO. 2013. Antiretroviral therapy for HIV in adults and adolescents. Recommendations for a public health approach 2010 revision. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf. Accessed 1 April 2013.
11. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S, Fidler S, Fisher M, Freedman A, Geretti AM, Gilleece Y, Horne R, Johnson M, Khoo S, Leen C, Marshall N, Nelson M, Orkin C, Paton N, Phillips A, Post F, Pozniak A, Sabin C, Trevelion R, Ustianowski A, Walsh J, Waters L, Wilkins E, Winston A, Youle M. 2012. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 13(Suppl 2):1-85.
12. Michaud V, Bar-Magen T, Turgeon J, Flockhart D, Desta Z, Wainberg MA. 2012. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol. Rev. 64:803-833. http://dx.doi.org/10.1124/pr.111.005553.
13. Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, Del Giudice P, Montagne N, Schapiro JM, Dellamonica P. 2000. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypicguided therapy: pharmacological data from the Viradapt study. AIDS 14: 1333-1339. http://dx.doi.org/10.1097/00002030-200007070-00005. (Pubitemid 30459505)
14. Fabbiani M, Bracciale L, Ragazzoni E, Santangelo R, Cattani P, Di Giambenedetto S, Fadda G, Navarra P, Cauda R, De Luca A. 2011. Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure. Infection 39:563-569. http://dx.doi.org/10.1007/ s15010-011-0183-8.
15. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. 2001. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71-75. http://dx.doi.org/10.1097/00002030-200101050-00011. (Pubitemid 32055781)
16. Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. 2013. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. Antimicrob. Agents Chemother. 57:1019-1024. http://dx.doi.org/10.1128/AAC.02023-12.
17. Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Decosterd L, Blievernicht J, Saussele T, Gunthard HF, Schwab M, Eichelbaum M, Telenti A, Zanger UM. 2007. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin. Pharmacol. Ther. 81:557-566. http://dx.doi.org/10.1038/sj.clpt.6100072. (Pubitemid 46454205)
18. Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, Fujimoto K, Sato I, Ueda M, Horiba M, Hamaguchi M, Yamamoto M, Takata N, Kimura A, Koike T, Gejyo F, Matsushita S, Shirasaka T, Kimura S, Oka S. 2007. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin. Infect. Dis. 45:1230-1237. http://dx.doi.org/10.1086/522175. (Pubitemid 47580326)
19. Sukasem C, Cressey TR, Prapaithong P, Tawon Y, Pasomsub E, Srichunrusami C, Jantararoungtong T, Lallement M, Chantratita W. 2012. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults. Br. J. Clin. Pharmacol. 74:1005-1012. http://dx.doi.org/10.1111/j. 1365-2125.2012.04288.x.
20. Stahle L, Moberg L, Svensson JO, Sonnerborg A. 2004. Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther. Drug Monit. 26:267-270. http://dx.doi.org/10.1097/ 00007691-200406000-00008. (Pubitemid 38703012)
21. Arab-Alameddine M, Di Iulio J, Buclin T, Rotger M, Lubomirov R, Cavassini M, Fayet A, Decosterd LA, Eap CB, Biollaz J, Telenti A, Csajka C, Swiss HIVCS. 2009. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin. Pharmacol. Ther. 85:485-494. http://dx.doi.org/10.1038/clpt.2008.271.
22. Cabrera SE, Santos D, Valverde MP, Dominguez-Gil A, Gonzalez F, Luna G, Garcia MJ. 2009. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob. Agents Chemother. 53:2791-2798. http://dx.doi.org/10.1128/AAC.01537- 08.
23. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD. 2008. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-U. S. A. panel. Clin. Infect. Dis. 47:266-285. http://dx.doi.org/10.1086/589297. (Pubitemid 351920631)
24. Manosuthi W, Sungkanuparph S, Tantanathip P, Mankatitham W, Lueangniyomkul A, Thongyen S, Eampokarap B, Uttayamakul S, Suwanvattana P, Kaewsaard S, Ruxrungtham K, Team NRS. 2009. Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin. Antimicrob. Agents Chemother. 53:4545-4548. http://dx.doi.org/10.1128/AAC.00492- 09.
25. Friedland G, Khoo S, Jack C, Lalloo U. 2006. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J. Antimicrob. Chemother. 58:1299-1302. http://dx.doi.org/10.1093/jac/dkl399. (Pubitemid 44884158)
26. Matteelli A, Regazzi M, Villani P, De Iaco G, Cusato M, Carvalho AC, Caligaris S, Tomasoni L, Manfrin M, Capone S, Carosi G. 2007. Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr. HIV Res. 5:349-353. http://dx.doi.org/10.2174/ 157016207780636588. (Pubitemid 46785071)
27. Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH. 2009. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 23:2101-2106. http://dx.doi.org/10.1097/QAD. 0b013e3283319908.